J Korean Med Sci.  2012 Oct;27(10):1261-1264. 10.3346/jkms.2012.27.10.1261.

Successful Treatment of Chronic Eosinophilic Pneumonia with Anti-IgE Therapy

• Shin YS
• Jin HJ
• Yoo HS
• Hwang EK
• Nam YH
• Ye YM
• Park HS

• KMID: 1778836
• DOI: http://doi.org/10.3346/jkms.2012.27.10.1261

Abstract

Anti-IgE therapy, using recombinant humanized anti-IgE antibodies, is clinically effective in patients with eosinophil-related disorders such as allergic asthma, allergic rhinitis, and chronic urticaria. Chronic eosinophilic pneumonia tends to respond promptly to systemic corticosteroid therapy, however; relapses are common following corticosteroid tapering. We treated two patients (17- and 19-yr-old males) of chronic eosinophilic pneumonia whose symptoms were cough and dyspnea on exertion. The symptoms were recurrent while tapering off corticosteroid. They were treated with anti-IgE antibody without recurrence for 2 yr and 15 months. Here, we first describe clinical experience of the 2 cases of chronic eosinophilic pneumonia.

Keyword

Chronic Eosinophilic Pneumonia; Anti-IgE Therapy

MeSH Terms

Adolescent
Adrenal Cortex Hormones/therapeutic use
Antibodies, Anti-Idiotypic/*therapeutic use
Cough/etiology
Dyspnea/etiology
Humans
Male
Pulmonary Eosinophilia/diagnosis/radiography/*therapy
Tomography, X-Ray Computed
Young Adult
Adrenal Cortex Hormones
Antibodies, Anti-Idiotypic

Figure

• 

  Fig. 1 The radiologic findings before and after anti-IgE antibody treatment. Multifocal ground glass opacity and nodular opacities were seen in both lungs on CXR and chest CT before anti-IgE antibody treatment. These findings were cleared after anti-IgE antibody treatment.

Reference

1. Allen JN, Davis WB. Eosinophilic lung diseases. Am J Respir Crit Care Med. 1994. 150:1423–1438.

2. Jederlinic PJ, Sicilian L, Gaensler EA. Chronic eosinophilic pneumonia. A report of 19 cases and a review of the literature. Medicine (Baltimore). 1988. 67:154–162.

3. Naughton M, Fahy J, FitzGerald MX. Chronic eosinophilic pneumonia. A long-term follow-up of 12 patients. Chest. 1993. 103:162–165.

4. Djukanovic R, Wilson SJ, Kraft M, Jarjour NN, Steel M, Chung KF, Bao W, Fowler-Taylor A, Matthews J, Busse WW, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med. 2004. 170:583–593.

5. Foroughi S, Foster B, Kim N, Bernardino LB, Scott LM, Hamilton RG, Metcalfe DD, Mannon PJ, Prussin C. Anti-IgE treatment of eosinophil-associated gastrointestinal disorders. J Allergy Clin Immunol. 2007. 120:594–601.

6. Nam YH, Kim JH, Jin HJ, Hwang EK, Shin YS, Ye YM, Park HS. Effects of omalizumab treatment in patients with refractory chronic urticaria. Allergy Asthma Immunol Res. 2012. 04. 20.

7. Plewako H, Arvidsson M, Petruson K, Oancea I, Holmberg K, Adelroth E, Gustafsson H, Sandstrom T, Rak S. The effect of omalizumab on nasal allergic inflammation. J Allergy Clin Immunol. 2002. 110:68–71.

8. Carrington CB, Addington WW, Goff AM, Madoff IM, Marks A, Schwaber JR, Gaensler EA. Chronic eosinophilic pneumonia. N Engl J Med. 1969. 280:787–798.

9. Massanari M, Holgate ST, Busse WW, Jimenez P, Kianifard F, Zeldin R. Effect of omalizumab on peripheral blood eosinophilia in allergic asthma. Respir Med. 2010. 104:188–196.

10. Noga O, Hanf G, Brachmann I, Klucken AC, Kleine-Tebbe J, Rosseau S, Kunkel G, Suttorp N, Seybold J. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. J Allergy Clin Immunol. 2006. 117:1493–1499.